The FDA announced July 28 it has approved Adlyxin, a daily injection to improve blood sugar levels in adults with type 2 diabetes.
Adlyxin (lixisenatide) is manufactured by Sanofi-Aventis U.S. LLC, based in Bridgewater, N.J., a subsidiary of Paris-based drugmaker Sanofi.
“The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose targets,” Peter Guenter, an executive vice president at Sanofi said in a July 27 statement.
“We are pleased with this approval, as it offers us the opportunity to continue helping patients ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.